Eyepoint Pharmaceuticals EYPT Stock Forecast 2023, 2024 and 2025

EYPT Stock Forecast 2023: Latest Price

Article Coverage: EYPT Stock Performance, Latest EYPT News, Aggregated Forecasts, EYPT Latest Production Update, Reasons to Buy or Sell EYPT Stock, EYPT Investor Day Analysis, FAQs and Other detailed analysis.

EyePoint Pharmaceuticals Inc (EYPT) is a pharmaceutical company that develops and commercializes ophthalmic products for the treatment of eye diseases. EyePoint Pharmaceuticals Inc (EYPT) went public on the Nasdaq stock exchange on February 25, 2021.

EYPT Stock Forecast 2023: Latest News

EyePoint Pharmaceuticals ($EYPT) participated in the 18th Annual BioPharma Conference hosted by Citi, where they engaged with global leaders to discuss their innovative technology designed to shape the future of ophthalmology.
EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, M.D., as President and Chief Executive Officer. Dr. Duker previously served as President and Chief Operating Officer of EyePoint.

EYPT Stock Forecasts

EYPT Stock Predictions 2023: Analysts

EYPT Target Price	$32
*Cantor Fitzgerald*	*$31*
*HC Wainwright & Co.*	*$27*
*Chardan Capital*	*$22*
*JonesTrading*	*$26*
*Guggenheim*	*$55*

EYPT Quarterly Financial Result

Q2 of 2023 Details

EyePoint Pharmaceuticals (EYPT) reported a quarterly loss of $0.61 per share, significantly missing the Zacks Consensus Estimate of $0.41, with an earnings surprise of -248.78%.

Revenues for the quarter came in at $9.11 million, falling short of the estimate by 88.48%. While EYPT stock has shown strong gains of 262.9% year-to-date, its future performance will hinge on management’s guidance.

The stock has outperformed the market so far this year, but the sustainability of this performance will depend on management’s commentary on the earnings call. The current consensus EPS estimate for the coming quarter is -$0.64 on $0.2 million in revenues. The current consensus EPS estimate for the current fiscal year is -$1.67 on $87.41 million in revenues.

It suggests that EYPT’s earnings performance has been weak, but the stock has outperformed the market so far this year. The sustainability of this performance will depend on management’s commentary on the earnings call and the outlook for the industry.

EYPT Last 4 Quarters Summary

(USD)	Jun 2023	Apr 2023	Dec 2022	Sep 2022
Revenue	9.10M	7.68M	10.5M	10M
Net income	-22.9M	-21.2M	-43.5M	-18.4M
Diluted EPS	–	–	-1.16	-0.49
Net profit margin	-251.73%	-275.47%	-412.53%	-183.98%
Operating income	-22.8M	-21.6M	-23M	-18.4M
Net change in cash	33.8M	10.1M	20.3M	-6.77M
Cost of revenue	17.2M	14M	17.9M	12.6M

EyePoint Pharmaceuticals Stock Forecast 2023, 2024 and 2025

EyePoint Pharmaceuticals Stock Price Prediction 2023 is $7.57
EyePoint Pharmaceuticals Stock Price Prediction 2024 is $12.3
EyePoint Pharmaceuticals Stock Price Prediction 2025 is $16.2

EYPT Stock Forecast 2023: Performance in the Last 12 Months

Last 6 Months: +211.1%
Last 12 Months: +3.3%
Year to Date (2023): +167.6%

Will EYPT reach $20 in 2023?

It is impossible to say for certain whether EYPT will reach $20 in 2023. The stock price is determined by a number of factors, including the company’s earnings performance, the outlook for the industry, and investor sentiment.

Based on the current consensus EPS estimate for the current fiscal year, EYPT would need to grow its earnings by over 1,000% in order to reach $20 per share. This is a tall order, but it is not impossible. The company has a number of promising products in its pipeline, and if they are successful, it could drive earnings growth.

However, there are also some risks to consider. The company is still in the early stages of development, and there is no guarantee that its products will be successful. Additionally, the industry is highly competitive, and EYPT faces competition from other pharmaceutical companies.

Overall, the chances of EYPT reaching $20 in 2023 are slim, but it is not impossible. The stock is a high-risk, high-reward investment.

EYPT Stock Forecast 2023: How High Will EYPT Go in 2023?

The current consensus analyst price target for EYPT is $30.00. This means that analysts believe that the stock has the potential to reach $30 per share in the next 12 months. However, it is important to note that analyst price targets are just estimates, and the actual stock price could go higher or lower than the target.

There are a number of factors that could contribute to EYPT reaching $30 per share in 2023. These include:

The company’s products are successful in clinical trials and are approved by the FDA.
The company signs partnerships with major pharmaceutical companies to market and distribute its products.
The company experiences strong growth in its revenue and earnings.
The overall stock market performs well.

Is EYPT a good stock to buy?

There are a few reasons why you might want to consider buying EYPT stock.

The company has a promising pipeline of products. EYPT is developing a number of products that could be blockbuster treatments for eye diseases. These include:
- EYP-1901, a sustained-release treatment for wet age-related macular degeneration (AMD), a leading cause of blindness in the elderly.
- PIMAX, a sustained-release treatment for glaucoma, a condition that damages the optic nerve and can lead to blindness.
- Abicipar sa, a sustained-release treatment for osteoarthritis, a condition that causes pain and inflammation in the joints.
The stock is undervalued. EYPT stock is currently trading at a significant discount to its peers. This could be a sign that the market is underestimating the potential of the company’s products.

EYPT Stock Forecast 2023: Reasons Not to Buy EYPT Stock

Here are some reasons why you might not want to buy EYPT stock:

The company is still in the early stages of development. There is no guarantee that any of EYPT’s products will be successful. The company is still in the clinical trial phase for most of its pipeline products, and there is no guarantee that they will be approved by the FDA.
The company faces competition from other pharmaceutical companies. There are other companies developing similar products to EYPT’s. This could make it difficult for EYPT to compete and gain market share.
The company is not yet profitable. EYPT is still incurring losses. This could be a sign that the company is not yet sustainable.
The stock is volatile. EYPT’s stock price has been volatile in the past. This means that the stock price could go up or down sharply in a short period of time.

EYPT Stock Forecast 2023: Frequently Asked Questions (FAQ)

Should I buy EYPT Stock now?

Whether or not you should buy EYPT stock now is a decision that only you can make. There are a number of factors to consider, including your investment goals, risk tolerance, and the overall market conditions.

Will EYPT Stock Go Up?

The future price of EYPT stock is uncertain and cannot be predicted with certainty. However, there are a number of factors that could contribute to the stock price going up.

The success of the company’s products
The company’s partnerships
Strong growth in the company’s revenue and earnings

How much will EYPT Stock be worth in 10 years?

It is impossible to say for certain how much EYPT stock will be worth in 10 years. The stock price is determined by a number of factors, including the company’s earnings performance, the outlook for the industry, and investor sentiment. However, based on the current consensus analyst price target of $30.00, EYPT stock could be worth between $30 and $50 per share in 10 years.

What is the best time to invest in EYPT Stock?

There is no one-size-fits-all answer to this question, as the best time to invest in EYPT stock will vary depending on your individual investment goals and risk tolerance. However, there are a few things to keep in mind when making this decision.

The company’s pipeline of products
The stock price
Your investment goals and risk tolerance
The overall market conditions

Note: Crowdwisdom360 collates Predictions and data from all over the net and has no in-house view on the likely trends in the Stocks or Crypto Coins. Please consult a registered investment advisor to guide you on your financial decisions.